A 12-month, open label, multicenter pilot study evaluating fingolimod treatment in terms of patient satisfaction in relapsing remitting multiple sclerosis patients-FINE trial


Akman Demir G., TÜRKOĞLU R., Saip S., Yüceyar N., EFENDİ H., Turan Ö. F., ...Daha Fazla

Noropsikiyatri Arsivi, cilt.56, sa.4, ss.253-257, 2019 (SCI-Expanded, Scopus, TRDizin)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 56 Sayı: 4
  • Basım Tarihi: 2019
  • Doi Numarası: 10.5152/npa.2017.20515
  • Dergi Adı: Noropsikiyatri Arsivi
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.253-257
  • Anahtar Kelimeler: Multiple sclerosis, fingolimod, patient satisfaction, quality of life
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Introduction: To assess satisfaction and quality of life in patients with relapsing–remitting multiple sclerosis (RRMS) who were receiving fingolimod (0.5 mg/day) for 12 months as a second-line treatment after switching from injectable agents. Methods: Patients aged 18–65 years with RRMS who fulfilled the eligibility criteria were enrolled from 16 centers throughout Turkey. Treatment Satisfaction Questionnaire for Medication and 36-item Short-Form Health Survey were completed at baseline and four visits to assess patient satisfaction and quality of life. Reselig (44.7±9.9) were significantly higher than those at baseline [32.0±9.9; (p<0.001)]. The only significant increase in the quality of life survey was in the emotional aspect (p=0.019). There were 124 adverse events and none of the five serious adverse events noted was considered drug-related. Conclusion: Large-scale comparative studies performed with disease specific quality of life instruments will allow more information on this issue.